Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus

Clinical Therapeutics

Volumn 38, Issue 1, 2016, Pages 66-88.e20

  Haneda, Masakazu ^a   Seino, Yutaka ^b   Inagaki, Nobuya ^c   Kaku, Kohei ^d   Sasaki, Takashi ^e   Fukatsu, Atsushi ^f   Kakiuchi, Haruka ^g   Sato, Yuri ^g   Sakai, Soichi ^g   Samukawa, Yoshishige ^g  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Yachiyo Hospital   (Japan)

^g TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Japanese; Key words glomerular filtration rate; luseogliflozin; renal impairment; sodium glucose cotransporter 2 inhibitor; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; C PEPTIDE; CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLUCOSE; GLYCOALBUMIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUSEOGLIFLOZIN; METFORMIN; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SODIUM GLUCOSE COTRANSPORTER; SORBITOL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETA 2 MICROGLOBULIN URINE LEVEL; BODY WEIGHT; BONE METABOLISM; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INCIDENCE; INSULIN BLOOD LEVEL; JAPANESE (PEOPLE); KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERE RENAL IMPAIRMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; JAPAN; KIDNEY FAILURE; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SODIUM-GLUCOSE TRANSPORT PROTEINS; SORBITOL; TREATMENT OUTCOME;

EID: 84954388588     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.10.025     Document Type: Article

References (40)

1. International Diabetes Federation. IDF Diabetes Atlas (6th edition). http://www.idf.org/sites/default/files/Atlas-poster-2014-EN.pdf. Accessed January 20, 2015.
2. Ministry of Health, Labor and Welfare. The National Health and Nutrition Survey in Japan, 2012. http://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h24-houkoku.pdf. Accessed January 20, 2015.
3. The Japanese Society for Dialysis Therapy. Facts of dialysis therapy in Japan: transition of primary disease in patients with dialysis (in Japanese). http://docs.jsdt.or.jp/overview/pdf2014/p011.pdf. Accessed January 20, 2015.
4. I.M. Stratton, A.I. Adler, H.A. Neil, and et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412
5. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study JAMA 290 2003 2159 2167
6. H. Yokoyama, S. Araki, J. Honjo, and et al. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria Diabetes Care 36 2013 3227 3233
7. Kidney disease improving global outcomes KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD Kidney Int 3 suppl 2013 91 111
8. Japanese Society of Nephrology. CKD practice guideline 2012. 14: The management of diabetic patients: 73-75. http://www.jsn.or.jp/guideline/pdf/CKDguide2012.pdf. Accessed April 1, 2015.
9. Committee on the Proper Use of Biguanides. Recommendation on the proper use of biguanides, revision at March 28, 2014. http://www.jds.or.jp/common/fckeditor/editor/filemanager/connectors/php/transfer.php?file=/uid000025-7265636F6D6D656E646174696F6E5F62696775616E6964652E706466. Accessed April 1, 2015.
10. H. Kakinuma, T. Oi, Y. Hashimoto-Tsuchiya, and et al. (1S)-1,5-anhydro-1- [45-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment J Med Chem 53 2010 3247 3261
11. K. Yamamoto, S. Uchida, K. Kitano, and et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity Br J Pharmacol 164 2011 181 191
12. B. Peene, and K. Benhalima Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes Ther Adv Endocrinol Metab 5 2014 124 136
13. Y. Seino, T. Sasaki, A. Fukatsu, and et al. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study Curr Med Res Opin 30 2014 1219 1230
14. Y. Seino, T. Sasaki, A. Fukatsu, and et al. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study Curr Med Res Opin 30 2014 1231 1244
15. Y. Seino, T. Sasaki, A. Fukatsu, and et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study Curr Med Res Opin 30 2014 1245 1255
16. Y. Seino, N. Inagaki, M. Haneda, and et al. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus J Diabetes Invest 6 2015 443 453
17. Y. Seino, K. Kaku, N. Inagaki, and et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise Endocr J 62 2015 593 603
18. S. Kasichayanula, X. Liu, M. Pe Benito, and et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus Br J Clin Pharmacol 76 2013 432 444
19. N. Inagaki, K. Kondo, T. Yoshinari, and et al. Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment Clin Drug Investig 34 2014 731 742
20. A. Sarashina, K. Ueki, T. Sasaki, and et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus Clin Ther 36 2014 1606 1615
21. S. Macha, M. Mattheus, A. Halabi, and et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment Diabetes Obes Metab 16 2014 215 222
22. E. Ferrannini, S.A. Veltkamp, R.A. Smulders, and T. Kadokura Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes Diabetes Care 36 2013 1260 1265
23. S. Matsuo, E. Imai, M. Horio, and et al. Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan Am J Kidney Dis 53 2009 982 992
24. A. Kashiwagi, M. Kasuga, E. Araki, and et al. Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values J Diabetes Investig 3 2012 39 40
25. D.E. Kohan, P. Fioretto, W. Tang, and J.F. List Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Kidney Int 85 2014 962 971
26. J.F. Yale, G. Bakris, B. Cariou, and et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 2013 463 473
27. H. Yamout, V. Perkovic, M. Davies, and et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy Am J Nephrol 40 2014 64 74
28. A.H. Barnett, A. Mithal, J. Manassie, et al. EMPA-REG RENAL Trial Investigators Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 2 2014 369 384
29. Z.T. Bloomgarden, R. Dodis, C.M. Viscoli, and et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis Diabetes Care 29 2006 2137 2139
30. G. Thomas, A.R. Sehgal, S.R. Kashyap, and et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis Clin J Am Soc Nephrol 6 2011 2364 2373
31. UK Prospective Diabetes Study(UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
32. F. Ismail-Beigi, T. Craven, M.A. Banerji, et al. ACCORD Trial Group Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 2010 419 430
33. ADVANCE Collaborative Group A. Patel, S. MacMahon, J. Chalmers, and et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
34. W. Duckworth, C. Abraira, T. Moritz, et al. VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
35. R. Boussageon, T. Bejan-Angoulvant, M. Saadatian-Elahi, and et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials BMJ 343 2011 d4169
36. H. Masugata, S. Senda, M. Inukai, and et al. Seasonal variation in estimated glomerular filtration rate based on serum creatinine levels in hypertensive patients Tohoku J Exp Med 224 2011 137 142
37. S. Anderson, T.W. Meyer, H.G. Rennke, and B.M. Brenner Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass J Clin Invest 76 1985 612 619
38. D.Z. Cherney, B.A. Perkins, N. Soleymanlou, and et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 129 2014 587 597
39. The Japanese Society of Hypertension. http://www.jpnsh.jp/data/jsh2014/jsh2014v1-1.pdf. Accessed January 20, 2015.
40. P.N. Van Buren, and R. Toto Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management Adv Chronic Kidney Dis 18 2011 28 41